Population effects of preventive and therapeutic HIV vaccines in early‐ and late‐stage epidemics

Objective: To evaluate the population effects of potential preventive and therapeutic vaccines in early‐ and late‐stage epidemics in a population of homosexual men. Methods: An epidemic model was used that simulated the course of the epidemic for a population of homosexual men in San Francisco, California. Vaccine programs were evaluated by the number of cases of HIV averted, the effect on the prevalence of HIV, and by the gain in quality‐adjusted life years (QALY) for the total population. Results: In the model, a preventive vaccine prevented 3877 cases of HIV infection during a 20‐year period, reduced the projected prevalence of HIV infection from 12 to 7% in a late‐stage epidemic, and gained 15 908 QALY. A therapeutic vaccine that did not affect the infectivity of vaccine recipients increased the number of cases of HIV infection by 210, resulted in a slight increase in the prevalence of HIV infection from 12 to 15% in a late‐stage epidemic, and gained 8854 QALY. If therapeutic vaccines reduced infectivity, their use could produce net gains of QALY in the population that were similar to gains from the use of preventive vaccines. In an early‐stage epidemic, the advantage of a preventive vaccine program relative to a therapeutic vaccine program was markedly enhanced. Conclusions: Both preventive and therapeutic vaccine programs provided substantial benefit, but their relative merit depended on which outcome measures were assessed. Evaluation of HIV vaccine programs based solely on cases averted or on prevalence of HIV in the population underestimates the benefit associated with therapeutic vaccine programs. The effect of a therapeutic HIV vaccine on the epidemic outcomes depended markedly on whether the therapeutic vaccine reduced the infectivity of the vaccine recipient. The relative merits of preventive and therapeutic vaccines depend on the stage of the epidemic. Field vaccine trials should evaluate correlates of infectivity, such as HIV viral load. HIV vaccine implementation strategies should be tailored to the dynamics of the epidemic in specific populations.

[1]  M. Nowak,et al.  A mathematical model of vaccination against HIV to prevent the development of AIDS , 1991, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[2]  T. Coates,et al.  Maintenance of safer sexual behaviors and predictors of risky sex: the San Francisco Men's Health Study. , 1990, American journal of public health.

[3]  G. Rutherford,et al.  The natural history of transfusion-associated infection with human immunodeficiency virus. Factors influencing the rate of progression to disease. , 1989, The New England journal of medicine.

[4]  R. Janssen,et al.  Seroprevalence of HIV and risk behaviors among young homosexual and bisexual men. The San Francisco/Berkeley Young Men's Survey. , 1994, JAMA.

[5]  A Fowler,et al.  A phase I evaluation of the safety and immunogenicity of vaccination with recombinant gp160 in patients with early human immunodeficiency virus infection. Military Medical Consortium for Applied Retroviral Research. , 1991, The New England journal of medicine.

[6]  Joan S. Chmiel,et al.  Acquired immunodeficiency syndrome (AIDS)-free time after human immunodeficiency virus type 1 (HIV-1) seroconversion in homosexual men. Multicenter AIDS Cohort Study Group. , 1989, American journal of epidemiology.

[7]  George W. Torrance,et al.  Social preferences for health states: An empirical evaluation of three measurement techniques , 1976 .

[8]  B. Haynes,et al.  Scientific and social issues of human immunodeficiency virus vaccine development. , 1993, Science.

[9]  J. Chin.  Current and future dimensions of the HIV/AIDS pandemic in women and children , 1990, The Lancet.

[10]  HIV/AIDS: figures and trends mid-1996 estimates. , 1996, Pediatric AIDS and HIV infection.

[11]  Lisa Sattenspiel,et al.  Modeling and analyzing HIV transmission: the effect of contact patterns , 1988 .

[12]  S. Blower,et al.  HIV transmission in sexual networks: an empirical analysis , 1995, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[13]  Douglas K Owens,et al.  Screening Women of Childbearing Age for Human Immunodeficiency Virus: A Model-Based Policy Analysis , 1993 .

[14]  Barney S. Graham,et al.  The Safety and Immunogenicity of a Human Immunodeficiency Virus Type 1 (HIV-1) Recombinant gp160 Candidate Vaccine in Humans , 1991 .

[15]  Ross D. Shachter,et al.  A dynamic model of HIV transmission for evaluation of the costs and benefits of vaccine programs , 1997 .

[16]  R. M. May,et al.  Potential of community-wide chemotherapy or immunotherapy to control the spread of HIV-1 , 1991, Nature.

[17]  K. Steimer,et al.  Safety and immunogenicity of a genetically engineered human immunodeficiency virus vaccine. , 1991, The Journal of infectious diseases.

[18]  J. Margolick,et al.  Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. , 1995, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

[19]  W Winkelstein,et al.  The San Francisco Men's Health Study: continued decline in HIV seroconversion rates among homosexual/bisexual men. , 1988, American journal of public health.

[20]  Sally M. Blower,et al.  Imperfect vaccines and herd immunity to HIV , 1993, Proceedings of the Royal Society of London. Series B: Biological Sciences.

[21]  M C Weinstein,et al.  Health values of patients infected with human immunodeficiency virus. Relationship to mental health and physical functioning. , 1996, Medical care.

[22]  S. Blower,et al.  Prophylactic vaccines, risk behavior change, and the probability of eradicating HIV in San Francisco. , 1994, Science.

[23]  Douglas K Owens,et al.  Medical decision making: probabilistic medical reasoning , 1990 .

[24]  J. Mann,et al.  Projections of HIV infections and AIDS cases to the year 2000. , 1990, Bulletin of the World Health Organization.

[25]  T. Philipson,et al.  Infectious disease transmission and infection-dependent matching. , 1998, Mathematical biosciences.

[26]  Patricia Scott,et al.  Screening Surgeons for HIV Infection: A Cost-effectiveness Analysis , 1995, Annals of Internal Medicine.

[27]  B. Graham,et al.  Candidate AIDS vaccines. , 1995, The New England journal of medicine.

[28]  R. Sperling.  Maternal Viral Load, Zidovudine Treatment, and the Risk of Transmission of Human Immunodeficiency Virus Type 1 from Mother to Infant. , 1997 .

[29]  Anthony S. Fauci,et al.  Toward an Understanding of the Correlates of Protective Immunity to HIV Infection , 1996, Science.